Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
New cancer vaccines study results reported from T.D. Szucs et al
July 9th, 2008
According to recent research from Lyon, France, "Based on positive safety and efficacy data, a quadrivalent Human PapillomaVirus (HPV) vaccine has been approved in Switzerland to prevent HPV types 6, 11, 16 and 18 infections. The objective of this study was to explore the cost-effectiveness of an HPV vaccination in Switzerland." "A Markov model of the natural history of HPV infection was adapted to the Swiss context and followed a hypothetical cohort of 41200 girls aged 11 years over their lifetime. Main epidemiological and economic parameters were extracted from the literature. Two strategies were compared: conventional cytological screening only and HPV vaccination...
Source: Vaccine Weekly (2008-07-09)
|
